32,941 Shares in Boston Scientific Corporation $BSX Acquired by Passumpsic Savings Bank

Passumpsic Savings Bank purchased a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the 4th quarter, HoldingsChannel reports. The institutional investor purchased 32,941 shares of the medical equipment provider’s stock, valued at approximately $3,141,000. Boston Scientific comprises about 1.7% of Passumpsic Savings Bank’s investment portfolio, making the stock its 19th biggest position.

Other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Boston Scientific by 0.8% in the third quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock valued at $13,497,294,000 after acquiring an additional 1,115,337 shares during the last quarter. Rathbones Group PLC increased its position in shares of Boston Scientific by 20.9% during the fourth quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock worth $263,133,000 after acquiring an additional 477,680 shares during the last quarter. Tounjian Advisory Partners LLC purchased a new stake in shares of Boston Scientific during the fourth quarter worth about $1,477,000. Kepler Cheuvreux Suisse SA purchased a new stake in shares of Boston Scientific during the third quarter worth about $26,955,000. Finally, Waycross Partners LLC purchased a new stake in shares of Boston Scientific during the fourth quarter worth about $2,384,000. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Trading Down 0.0%

NYSE BSX opened at $52.67 on Monday. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The company has a market capitalization of $78.27 billion, a PE ratio of 22.04, a price-to-earnings-growth ratio of 0.97 and a beta of 0.62. Boston Scientific Corporation has a 1-year low of $52.52 and a 1-year high of $109.50. The firm’s fifty day simple moving average is $63.40 and its 200-day simple moving average is $81.65.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.79 by $0.01. The firm had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business’s quarterly revenue was up 11.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, sell-side analysts anticipate that Boston Scientific Corporation will post 3.38 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on BSX. Oppenheimer set a $90.00 price target on Boston Scientific in a research report on Thursday, April 23rd. Canaccord Genuity Group decreased their price objective on Boston Scientific from $109.00 to $71.00 and set a “buy” rating for the company in a report on Thursday, April 23rd. Robert W. Baird cut their target price on Boston Scientific from $86.00 to $78.00 and set an “outperform” rating for the company in a research report on Thursday, April 23rd. Raymond James Financial restated an “outperform” rating and issued a $88.00 target price (down from $97.00) on shares of Boston Scientific in a research report on Monday, March 30th. Finally, Sanford C. Bernstein reiterated an “outperform” rating and set a $112.00 price objective on shares of Boston Scientific in a research report on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, Boston Scientific currently has an average rating of “Moderate Buy” and an average target price of $93.91.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.